Cell & Gene Therapy Market to Reach USD 131.7 Billion by 2034, Growing from USD 22.0 Billion in 2025 - SRI

London, UK - August 2026 | Strategic Revenue Insights Inc. - A single CAR-T therapy approval can turn a once-untreatable blood cancer into a curable condition, and that kind of clinical breakthrough is what's pulling pharmaceutical R&D budgets toward cell and gene therapy faster than almost any other segment of medicine. That momentum is reflected in the market's scale: the cell and gene therapy market was valued at USD 22.0 billion in 2025 and is projected to reach USD 131.7 billion by 2034, growing at a CAGR of 22.00% between 2026 and 2034, according to a new report from Strategic Revenue Insights Inc. The findings are led by lead analyst Lukas Schmidt, and the report is built on primary interviews with hospitals and specialized treatment centers, cancer and research institutes, and contract development and manufacturing organizations, combined with secondary research spanning Asia Pacific, North America, Latin America, Europe, and Middle East & Africa.

Key Takeaways

• The cell and gene therapy market is valued at USD 22.0 billion in 2025 and is forecast to reach USD 131.7 billion by 2034, at a CAGR of 22.00%, one of the fastest growth rates in this report series.
• Oncology applications lead the market, while Gene Therapy (In Vivo) is the fastest-growing therapy-type segment.
• Digital transformation is facilitating the development and delivery of increasingly complex, personalized therapies.
• North America leads the market, while Asia Pacific is emerging as a lucrative growth region.
• Novartis, Gilead Sciences, and Bristol Myers Squibb are among the leading providers shaping the competitive landscape.

Full report access: https://www.strategicrevenueinsights.com/industry/cell-gene-therapy-market

Precision Medicine and Genetic Research Advances Are Fueling Rapid Expansion

The clearest driver behind this market is the growing focus on precision medicine, which aims to tailor treatments to individual patients based on their genetic makeup. This approach is gaining traction for its potential to improve patient outcomes while reducing overall healthcare costs, and pharmaceutical companies are responding by investing heavily in cell and gene therapies as core components of their precision medicine strategies. The rising global prevalence of chronic diseases is compounding this demand, as patients and providers increasingly look for therapies that offer long-term benefits rather than ongoing symptom management.

Advances in genetic research and delivery technology are reinforcing this growth. Innovations in vector development and gene-editing techniques are expanding what's clinically possible, and digital transformation across healthcare is helping companies develop and deliver these increasingly complex therapies more efficiently. Favorable regulatory frameworks are also playing a meaningful role, with governments implementing policies that support both the development and commercialization of cell and gene therapies, creating a more conducive environment for companies to bring new treatments to market.

A third dynamic shaping the market is the growing emphasis on sustainability and evolving manufacturing strategies. Companies are investing in eco-friendly manufacturing processes and advanced logistics solutions to ensure efficient therapy distribution, while many are also weighing localization against globalization in their operations, with some establishing regional manufacturing facilities to reduce transportation costs and minimize the risk of supply chain disruption.

Market Segmentation

By therapy type, Oncology-focused Cell Therapy is gaining significant traction given its potential to treat cancer and autoimmune disorders, while Gene Therapy (In Vivo) is the fastest-growing segment as genetic research advances and delivery methods improve; Gene-Modified Cell Therapy (Ex Vivo) and Tissue-Engineered Products round out the therapy landscape, with the latter still in earlier stages of development but holding promise for regenerative medicine.

By vector type, Adeno-Associated Virus vectors are widely used given their safety profile and effective delivery of genetic material, while Lentivirus vectors are gaining popularity for hematologic disorders and certain cancers due to their stable gene integration; Retrovirus vectors continue to serve applications requiring stable gene expression, and Non-Viral Delivery methods are emerging as a promising alternative that could help overcome limitations of traditional viral vectors.

By application, Oncology dominates the market given rising cancer prevalence and demand for targeted therapies such as CAR-T treatments, while Rare & Genetic Diseases represent a significant application area as gene therapies target the underlying causes of these conditions; Hematologic Disorders, Neurological Disorders, Ophthalmology, Cardiovascular, and Autoimmune Conditions are all active areas of therapy development and research.

By end use, Hospitals & Specialized Treatment Centers are the primary end users given the infrastructure and expertise required to administer advanced therapies, while Cancer & Research Institutes play a crucial role in clinical trials and scientific advancement; Contract Development & Manufacturing Organizations are becoming increasingly important as they support the specialized manufacturing needs of complex cell and gene therapies.

Regional Outlook

North America dominates the market due to advanced healthcare infrastructure and strong research capabilities, while Asia Pacific is emerging as a lucrative growth market, driven by increasing healthcare expenditure, a rising patient population, and supportive government policies. Europe, Latin America, and the Middle East & Africa round out the report's regional coverage, each contributing to overall market expansion as regional manufacturing capacity and treatment access continue to grow.

Competitive Landscape

Novartis has made significant strides in the market with its CAR-T cell therapy Kymriah, reflecting a broader commitment to innovation and patient-centric solutions that has positioned it as a frontrunner in the industry. Gilead Sciences has strengthened its position through its acquisition of Kite Pharma, a pioneer in cell therapy, expanding its product portfolio and competitive standing. Bristol Myers Squibb has been actively developing novel therapies for cancer and other diseases, with its acquisition of Celgene further bolstering its pipeline of cell and gene therapies.

Market Restraints

The market's growth is tempered by the high cost of developing and manufacturing these therapies, which can limit accessibility and affordability for patients. The complex regulatory landscape and stringent approval processes add a further constraint, posing significant barriers to market entry for newer companies.

Related Reports

https://www.strategicrevenueinsights.com/industry/uncooked-pasta-and-noodles-market

https://www.strategicrevenueinsights.com/industry/weight-loss-supplement-market

https://www.strategicrevenueinsights.com/industry/3d-virtual-commerce-market

https://www.strategicrevenueinsights.com/industry/5g-fixed-wireless-access-market

https://www.strategicrevenueinsights.com/industry/accounts-receivable-automation-market

Frequently Asked Questions

How big is the cell and gene therapy market?

The market was valued at USD 22.0 billion in 2025 and is projected to reach USD 131.7 billion by 2034, growing at a CAGR of 22.00%.

What is driving growth in the cell and gene therapy market?

Growth is driven by the increasing prevalence of chronic diseases and the demand for personalized medicine.

Which region leads the cell and gene therapy market?

North America leads the market, while Asia Pacific is emerging as a fast-growing region.

Who are the leading companies in the cell and gene therapy market?

Leading companies named in the report include Novartis, Gilead Sciences, and Bristol Myers Squibb.

About Strategic Revenue Insights Inc.

Strategic Revenue Insights Inc., part of SRI Consulting Group Ltd, is a London-headquartered market intelligence firm that helps organizations across industries and geographies make evidence-based revenue and strategy decisions. The firm produces syndicated research reports and customized consulting engagements built on rigorous market sizing, forecasting, and competitive benchmarking, drawing on a globally connected team of analysts and consultants.

Media Contact Information

Company Name: Strategic Revenue Insights Inc.

Contact Person: Rohit Bhisey

Email: sales@strategicrevenueinsights.com

Phone: +44-787-740-3352

Address: Suite 10, Capital House, 61 Amhurst Road, London, E8 1LL, United Kingdom

Corporate Websites:

www.strategicrevenueinsights.com

www.strategicpackaginginsights.com

www.sriconsultinggroupltd.com

https://strategicrevenueinsights.blog/

https://medium.com/@strategic-revenue-insights.inc

https://www.strategicrevenueinsights.com/press-releases